Global CAR T-cell Therapy Market OverviewThe global CAR T-cell therapy market is poised for exceptional growth, with an ...
Collaboration leverages OBT's proprietary OGAP®-Verify discovery platform and drug development capabilities in alignment with BMS’s expertise to advance selected novel oncology targets This is OBT’s ...
Title: A novel and versatile Prodrug T cell engager platform with a novel candidate demonstrating potent and tumor-restricted activity Presentation Time: 9:00AM - 12:00PM, local time (Location: Poster ...
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular ...
Adds dedicated business development leadership to support Tempest’s strategic prioritiesWill lead China outreach and ...
Verismo Therapeutics, a clinical-stage CAR T cell therapy company pioneering a novel multi-chain KIR-CAR platform technology, ...
The dosing of these two patients demonstrates Cellares’ GMP manufacturing and supply chain capabilities with their automated platform.
The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of ...
EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T-cell engagers, is pleased to announce that the ...
The trial involves a PSMA-directed T cell engager using Janux’s tumour-activated platform to activate T cells.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results